Literature DB >> 8774498

Thrombosis in otherwise well children with the factor V Leiden mutation.

M T Sifontes1, R Nuss, L J Jacobson, J H Griffin, M J Manco-Johnson.   

Abstract

OBJECTIVE: To determine whether resistance to activated protein C caused by the factor V Leiden mutation (Arg506 to Gln) is associated with thrombosis occurring during childhood. STUDY
DESIGN: Children with thrombosis were screened for activated protein C resistance. Children found resistant to activated protein C had DNA analysis for the factor V Leiden mutation. Family members of the children with activated protein C resistance were similarly studied.
RESULTS: Three of fourteen children examined had abnormal normalized activated protein C sensitivity ratios. One child had protein S deficiency. The children had hyperlipidemia. Molecular confirmation of the factor V Leiden mutation was obtained for all three children. Family members of each of the three children were affected.
CONCLUSIONS: Children have thromboses in association with the factor V Leiden mutation, as do adults. This mutation may be identified as an isolated risk factor or in association with other risk factors for thrombosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774498     DOI: 10.1016/s0022-3476(96)70275-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Congenital thrombophilia and thrombosis: a study in a single centre.

Authors:  S E Lawson; D Butler; M S Enayat; M D Williams
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

2.  Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study.

Authors:  Gili Kenet; Fenella Kirkham; Thomas Niederstadt; Achim Heinecke; Dawn Saunders; Monika Stoll; Benjamin Brenner; Christoph Bidlingmaier; Christine Heller; Ralf Knöfler; Rosemarie Schobess; Barbara Zieger; Guillaume Sébire; Ulrike Nowak-Göttl
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.